a non-viral approach to genetically modify CAR-T cells. Shedding the CAR-T projects means Merck can concentrate on the development of its PD-L1 inhibitor Bavencio (avelumab) – partnered with ...

Merck's Keytruda could face competition from a newer medicine. The company's crown jewel will also lose patent exclusivity in a few years. Merck should have the means to get around these headwinds ...

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

Merck's combination of a wide lineup of high-margin drugs and a pipeline of new drugs should ensure strong returns on invested capital over the long term. Further, following the divestment of the ...

Merck (MRK) reachead $106.64 at the closing of the latest trading day, reflecting a +0.28% change compared to its last close. Visa, Netflix, Merck and Hovnanian are included in this Analyst Blog ...

Gilead Sciences (GILD) and Merck (MRK) announced new results from a Phase 2 clinical study evaluating the investigational combination of islatravir, an investigational nucleoside reverse ...

Merck & Co. has picked up options on two Evaxion Biotech vaccine candidates, paying $3.2 million and dangling more than $1 billion in milestones for the chance to pick up preclinical prospects ...

Sept 25 (Reuters) - Merck (MRK.N), opens new tab said on Wednesday a combination of its experimental drug and blockbuster therapy Keytruda failed a late-stage trial testing it in previously ...

(RTTNews) - Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the investigational combination of islatravir, an investigational ...

Also Read: Merck’s Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer. At the final pre-specified analysis, the favezelimab and pembrolizumab fixed-dose combination did not ...

DOLLARS vs HORSEPOWER. Where is the sweet spot? Worth It- MODS! (Porsche GT3RS) In this new video from Vin Anatra on YouTube, he explores that tipping point by comparing a stock Porsche 997 GT3 RS ...

The strength of Schonfeld et al is that it combines 4 large prospective trials that included a huge number of patients and cancers. A limitation is that although the women were part of prospective ...